The table below shows Viking Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$278.69M
-$87.79M
-$73.38M
-$48.40M
-$47.59M
-$21.78M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
$341.39M
-$553.37M
-$179.09M
$54.75M
$37.96M
$41.57M
Dividends paid
-
-
-
-
-
-
VKTX operating cash flow (10-K history)
Viking Therapeutics, Inc. reported operating cash flow of -$278.69M for fiscal year 2025. That is down 217.4% from -$87.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$14.76M (FY 2017) to -$278.69M. Figures come from the company's audited annual reports as filed with the SEC.
